suPAR is useful for risk stratification and treatment guidance of COVID-19 patients

An increasing number of studies find suPAR useful for risk stratification and treatment guidance of COVID-19 patients:

  • suPAR is an early predictor of some of the most critical COVID-19 outcomes:
  • Occurrence of severe respiratory failure and need for mechanical ventilation1
  • Development of acute kidney injury and requirement for dialysis2
  • suPAR can also be used to guide treatment by early identification of patients at risk of COVID-19-caused pneumonia develops into respiratory failure3

Using admission suPAR levels for COVID-19 patients, physicians can identify low-risk patients for early discharge to reduce the pressure on COVID-19 hospitals, i.e., at emergency departments and in intensive care units 4,5. Furthermore, using suPAR in triaging, physicians can identify high-risk patients early.

COVID-19 hospitals using suPAR for risk stratification might experience:

  • Improved patient care with fewer unnecessary admissions, fewer re-admissions, early treatment intervention, and shorter length-of-stay
  • Empowered clinical staff with more information to make confident decisions reducing stress and uncertainty
  • Reduced healthcare costs

“suPAR can be a strong tool for the much-needed early risk stratification of patients with COVID-19.”

Prof. Ove Andersen, MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark. suPAR News Vol. 3, June 2020

How to interpret suPAR results in the COVID-19 department

< 4

suPAR level below 4 ng/ml

Supports discharge

> 6

suPAR level above 6 ng/ml

Supports hospitalization